最新消息分類研發臨床進展

漢康生技HCB206拓展自體免疫疾病應用，加速推進臨床前關鍵試驗 HanchorBio Expands HCB206 Development into Autoimmune Diseases and Advances IND-Enabling Studies

HanchorBio announced that its internally developed dual-target fusion protein candidate, HCB206, has demonstrated therapeutic potential in preclinical studies across both oncology and autoimmune disease models.

5 月 11, 2026

漢康生技與河北清華發展研究院展開 HCB101 作用機制研究合作 HanchorBio Launches HCB101 Mechanism Collaboration Study with Tsinghua University

HanchorBio started a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.

5 月 05, 2026

漢康生技於台灣癌症聯合年會 (TJCC) 展現次世代合併治療骨幹潛力、腫瘤以外平台拓展與三特異性機制進展 HanchorBio Highlights Next Generation Combination Backbone Potential, Platform Expansion Beyond Oncology, and Tri-specific Mechanistic Progress at TJCC 2026

HanchorBiopresented at the 30th Taiwan Joint Cancer Conference (TJCC 2026). Across a keynote lecture and the company symposium, HanchorBio highlighted clinical and translational data supporting HCB101 as a clinically versatile innate immune backbone and presented a working mechanism framework for its next-generation tri-specific program, HCB301.

5 月 04, 2026

漢康生技與陽明交大啟動AI賦能藥物研發合作　推進次世代創新生物藥開發 HanchorBio and NYCU Launch AI-Enabled Drug Discovery Collaboration to Advance Next-Generation Biologics

HanchorBio started a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.

4 月 29, 2026

漢康生技發布 HCB101 頭頸癌數據：單藥展現持久活性，低劑量聯合 PD-1 觀察到完全緩解 HanchorBio Reports Head and Neck Cancer Data for HCB101, Including Durable Monotherapy Activity and Complete Response at Low Dose in Combination with PD-1

HanchorBio reported updated clinical observations in head and neck squamous cell carcinoma (HNSCC) across both monotherapy and combination settings for HCB101, its rationally engineered SIRPα-Fc fusion protein functioning as an innate immune checkpoint blockade.

4 月 22, 2026

漢康生技報告2026年上半年科學溝通成果，並預告第二季將參與多項學術會議HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation

HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.

4 月 20, 2026

漢康生技宣布 HCB101 完成首次 2,000 公升臨床用藥 GMP 批次生產 HanchorBio Announces Successful Completion of First 2,000L GMP Clinical Batch Production of HCB101

HanchorBio's HCB101, one of its core FBDB™ (Fc-Based Designer Biologics) oncology pipeline assets, has successfully completed its first GMP clinical batch production scaled up from a 500L to a 2,000L bioreactor. This production was carried out at WuXi Biologics’ manufacturing facility, covering the full process from Drug Substance (DS) to Drug Product (DP), and achieved all predefined manufacturing objectives.

4 月 14, 2026

漢康生技 HCB301 於台灣完成第一期臨床試驗首位患者給藥HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301

HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.

4 月 08, 2026

HanchorBio Signals “Backbone” Potential for HCB101 as SAB Aligns on Gastric Cancer Registrational Path隨著科學顧問委員會（SAB）就胃癌藥證註冊路徑達成共識，漢康生技釋出 HCB101 具備「治療骨幹療法」潛力的明確訊號

HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.

4 月 03, 2026

HanchorBio Reports Early Taiwan IIT Signal in 2L CRC With Sustained Disease Control Beyond 37 Weeks漢康生技公布台灣研究者發起的臨床研究於二線大腸直腸癌之早期訊號，疾病控制可持續超過 37 週

HanchorBio today announced early findings from an ongoing investigator-initiated trial (IIT) in Taiwan evaluating HCB101-based combination therapy in patients with second-line colorectal cancer (CRC).

4 月 03, 2026